Results 261 to 270 of about 29,210 (297)

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

Lancet Oncology, The, 2019
Carol Moreno, Richard F Greil, Fatih Demirkan   +2 more
exaly   +2 more sources

Role of Autologous Stem Cell Transplantation in the Context of Ibrutinib-Containing First-Line Treatment in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network

Blood
On behalf of the European MCL Network, ML and EH contributed equally Introduction: In younger patients with mantle cell lymphoma (MCL), the addition of ibrutinib during induction immuno-chemotherapy and as 2-years maintenance with and without ...
M. Dreyling, J. Doorduijn, Eva Giné, M. Jerkeman, J. Walewski, Martin Hutchings, Ulrich Mey, J. Riise, M. Trněný, V. Vergote, D. Donnarumma, O. Shpilberg, Maria Gomes da Silva, S. Leppä, Linmiao Jiang, Christiane Pott, W. Klapper, Christian Schmidt, M. Unterhalt, M. Ladetto, E. Hoster   +20 more
semanticscholar   +1 more source

Ibrutinib in the management of Waldenstrom macroglobulinemia

Journal of Oncology Pharmacy Practice, 2018
Bruton tyrosine kinase plays a critical role in hastening cell proliferation. Bruton tyrosine kinase inhibitors are a class of immunotheraputic agents that disrupt this signaling pathway. Ibrutinib, a novel Bruton tyrosine kinase inhibitor approved by the Food and Drug Administration (FDA) for the treatment of Waldenstrom macroglobulinemia in patients
Amir Yosef, Emily Z Touloukian, Vinod E Nambudiri   +2 more
openaire   +3 more sources

The Muddied Waters of Ibrutinib Therapy

Acta Haematologica, 2019
A 37-year-old male was admitted with an atypical presentation of central nervous system (CNS) aspergillosis while on ibrutinib therapy for a CNS relapse of mantle cell lymphoma. This case highlights the importance of a high clinical suspicion of opportunistic infections in patients receiving small-molecule kinase inhibitors.
Miri Schamroth Pravda, Nili Schamroth Pravda, Michael Lishner   +2 more
openaire   +3 more sources

Enantioseparation and ecotoxicity evaluation of ibrutinib by Electrokinetic Chromatography using single and dual systems.

Talanta: The International Journal of Pure and Applied Analytical Chemistry, 2023
In this work, two chiral methods enabling the separation of ibrutinib enantiomers were developed by Electrokinetic Chromatography. A cyclodextrin (CD) or a mixture of the CD and a chiral ionic liquid (CIL) was used as chiral selector. Using the single CD
L. García-Cansino, K. Boltes, M. Marina, Maria A. García   +3 more
semanticscholar   +1 more source

Long‐term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity

Cancer, 2023
Continuous ibrutinib administration is needed to maintain efficacy in patients with chronic lymphocytic leukemia (CLL) and, as such, long‐term toxicity is a concern. The authors report the 5‐year follow‐up of patients with CLL who received treatment with
M. Gordon, Jade E Jones, Binsah S George, C. Peterson, J. Burger, N. Jain, M. Keating, W. Wierda, J. Durand, A. Ferrajoli   +9 more
semanticscholar   +1 more source

Ibrutinib

2017
Ibrutinib (Imbruvica, Pharmacyclics, Janssen) is the first-in-class irreversible inhibitor of Bruton's tyrosine kinase (BTK), which is positioned downstream of the BCR at the cell surface of normal and malignant B-cells. In 2013, the Food and Drug Administration (FDA) granted accelerated approval for the treatment of mantle-cell lymphoma (MCL), and in ...
openaire   +2 more sources

Three years of ibrutinib in CLL

Blood, 2015
In this issue of Blood, Byrd et al provide an important update on the prolonged efficacy and the limited and reducing toxicity of the single-agent Bruton tyrosine kinase inhibitor ibrutinib in chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma patients who are followed for a median time of 3 years from start of treatment.
openaire   +4 more sources

Ibrutinib and Cardiac Arrythmias

2021
Patient was a 60-year-old male presented with palpitation. He had background history of diabetes type 2, obstructive sleep apnea on CPAP and hypertension.
openaire   +2 more sources

Ibrutinib for Mantle Cell Lymphoma

Future Oncology, 2016
Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin lymphoma. Ibrutinib is a first-in-class, oral inhibitor of Bruton's tyrosine kinase which acts by downstream inhibition of the B-cell receptor. Early clinical trials have demonstrated excellent tolerability and a modest side-effect profile in relapsed/refractory MCL.
David L. Tucker, Simon Rule
openaire   +3 more sources